Multimedia

Here you will find the current audio feeds from Vetter on some of the crucial topic in the international pharmaceutical and biotechnology fields.

• Audio: Vetter Chicago Site is Fully Operational Featuring State-Of-The-Art Technology, Including the First-Of-Its-Kind Fully Automatic Vial Filler.
  Peter Soelkner, Vetter Managing Director, in an interview with Pharmaceutical Technology gives the listener an insiders “tour” of the new facility, which is designed to provide customers with technology that minimizes loss of high-value API and helps shorten time to clinic. Featured at the site is Vetter’s new state-of-the-art fully automated vial filler, designed for clinical-stage, high value biopharmaceuticals. The filler, along with the sites three cleanrooms and microbiology and chemical analysis laboratories, demonstrate Vetter’s ongoing commitment to consistency and quality across all its manufacturing sites.
• Audio: Choosing a CDMO: Criteria to Help the Selection Process
  Today, perhaps more than ever before, developing and manufacturing innovative compounds involves considerable risks. For smaller biotech companies faced with limited financial resources, expertise, people and equipment the decisions they make can often determine the very life or death of their company. In a podcast interview with BIO, Peter Soelkner, Managing Director of Vetter discusses how a Contract Development Manufacturing Organization (CDMO) can be of vital support to such companies by helping them manage processes and facilitate creative decision-making during the early drug development period. Attributes to be considered are also provided to help ensure the right choice is made.
• Audio: Taking secondary packaging to a whole new level
  New Pharmaceutical Technology podcast
  Fedra Pavlou of Pharmaceutical Technology interviews Managing Director Thomas Otto on the advanced thinking behind the Vetter Secondary Packaging facility, including details on its leading-edge design, services and capacity. Otto discusses how the facility’s construction decreases the risk of contamination and mix-ups, as well as how Vetter stays abreast of increasingly rigorous regulation – including stringent requirements for cosmetic integrity in markets such as Japan.
• Audio: The role of VDS Chicago in the changing biotech arena
  Pharmaceutical Technology podcast
  Fedra Pavlou of Pharmaceutical Technology interviews Managing Director Peter Soelkner on the progress of Vetter’s new Chicago facility, including details about its used filling capacities. Soelkner discusses the specialized needs of a swiftly changing biotechnology industry – and the growing strength of America’s Midwest as a biotech powerhouse.  
• Audio: Background and services of Vetter Development Services USA Inc.
  The phase of clinical studies is crucial for new drugs. In order to minimize risks and take advantage of opportunities, you need broad know-how and years of experience. Vetter is a specialist in aseptic filling, and the new production facility, Vetter Development Services USA Inc., will be offering production of samples for preclinical and clinical phases I and II. Vetter Managing Director Peter Soelkner was at the annual meeting of the AAPS 2009 in Los Angeles, where he met with Fedra Pavlou, editor in chief of Pharmaceutical Technology Europe, to discuss Vetter's new site in the USA. 

• Audio: Why Vetter is expanding its production capability in Chicago
  The North American pharmaceuticals market is the world's largest and most important, with many new drugs currently being developed there. Vetter will use its Chicago subsidiary to support its customers during this critical development period. In a podcast interview for the BIO International Convention 2010 in Chicago, Managing Director Peter Soelkner discusses the new facility’s background and services.